Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia

Clinical Infectious Diseases

Volumn 38, Issue 9, 2004, Pages 1328-1330

  Khosrovaneh, Amir ^a   Riederer, Kathleen ^a   Saeed, Sajjad ^a   Tabriz, M Shame ^a   Shah, Amar R ^a   Hanna, Michel M ^a   Sharma, Mamta ^a   Johnson, Leonard B ^a   Fakih, Mohammad G ^a   Khatib, Riad ^a  

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METICILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG SCREENING; DRUG SENSITIVITY; IC 50; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; DRUG EFFECT; HUMAN; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; PENICILLIN RESISTANCE; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG RESISTANCE, MULTIPLE; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 2342447912     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/383036     Document Type: Article

References (12)

1. Tallent SM, Bischoff T, Climo M, Ostrowsky B, Wenzel RP, Edmond MB. Vancomycin susceptibility of oxacillin-resistant Staphylococcus aureus isolates causing nosocomial bloodstream infections. J Clin Microbiol 2002; 40:2249-50.
2. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40:135-6.
3. Kralovic SM, Danko LH, Roselle GA. Laboratory reporting of Staphylococcus aureus with reduced susceptibility to vancomycin in United States Department of Affairs facilities. Emerg Infect Dis 2002; 8:402-7.
4. Hubert SK, Mohammed JM, Fridkin SK, Gaynes RP, McGowan JE, Tenover FC. Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected US hospitals. J Clin Microbiol 1999; 37:3590-3.
5. Hussain FM, Boyle-Vavra S, Shete PB, Daum RS. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. J Infect Dis 2002; 186:661-7.
6. Sieradzki K, Leski T, Dick J, Borio L, Tomasz A. Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J Clin Microbiol 2003; 41:1687-93.
7. Kim HB, Park WB, Lee KD, et al. National surveillance for Staphylococcus aureus with reduced susceptibility to vancomycin in Korea. J Clin Microbiol 2003; 42:2279-81.
8. Sharma M, Riederer K, Johnson LB, Khatib R. Molecular analysis of coagulase-negative Staphylococcus isolates from blood cultures: prevalence of genotypic variation and polyclonal bacteremia. Clin Infect Dis 2001; 33:1317-23.
9. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001; 47:399-403.
10. Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 2003; 187:929-38.
11. Schwaber MJ, Wright SB, Carmeli Y, et al. Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerg Infect Dis 2003; 9:657-64.
12. Aucken HM, Warner M, Ganner M, et al. Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother 2000; 46:639-40.